Nucleic acids encoding chimeric CD154 polypeptides

Details Nucleic acids encoding chimeric CD154 polypeptides Nucleic acids encoding chimeric CD154 polypeptides

2002-05-23

2009-02-24

Gambel, Phillip (Department: 1644)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S023100, C536S023500, C435S252300, C435S320100, C435S455000

Reexamination Certificate

active

07495090

ABSTRACT:
The present invention provides for an isolated polynucleotide sequence encoding a chimeric CD154, comprising a first nucleotide sequence encoding an extracellular subdomain of non-human CD154, preferably murine CD154, that replaces a cleavage site of human CD154, and a second nucleotide sequence encoding an extracellular subdomain of human CD154 that binds to a human CD154 receptor. The present invention also provides for the chimeric CD154 that is encoded by the above-described polynucleotide sequence, an expression vector and a genetic vector comprising the polynucleotide sequence, a host cell comprising the expression vector or the genetic vector, a process for producing the chimeric CD154, and methods for utilizing the expression vectors and genetic constructs containing the chimeric CD154 polynucleotide sequences.

REFERENCES:
patent: 5716805 (1998-02-01), Srinivasan et al.
patent: 5962406 (1999-10-01), Armitage et al.
patent: 7070771 (2006-07-01), Kipps et al.
patent: 2002/0022017 (2002-02-01), Yu
patent: WO 98/26061 (1998-06-01), None
Skolnick et al., Trends in Biotech., 18(1):34 39, 2000.
International Search Report from international application PCT/US03/16305.
Armitage et al., “CD40 ligand is a T cell growth factor.” Eur. J. Immunol., 23:2326-2331, 1993.
Aruffo et al., “The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-lgM syndrome.” Cell, 72:291-300, 1993.
Banchereau et al., “The CD40 antigen and its ligand.” Annual Review Immunol., 12:881-922, 1994.
Cantwell et al., “Acquired CD40-ligand deficiency in chronic lymphocytic leukemia.” Nat. Med. 3:984-989, 1997.
Castle et al., “Regulation of expression of the ligand for CD40 on T helper lymphocytes.” J. Immunol., 151:1777-1788, 1993.
Dilloo et al., “CD40 ligand induces an antileukemia immune response in vivo.” Blood, 90:1927-1933, 1997.
Grewal et al., “CD40 and CD154 in cell-mediated immunity.” Annual Review of Immunology, 16:111-135, 1998.
Hermann et al., “Expression of a 32-kDa ligand for the CD40 antigen on activated human T lymphocytes.” Eur. J. Immunol., 23:961-964, 1993.
Hirano et al., “Inhibition of human breast carcinoma growth by a soluable recombinant human CD40 ligand.” Blood, 93: 2999-3007, 1999.
Kato et al., “Gene transfer of C40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells.” J. Clin. Invest., 101:1133-1141, 1998.
Kikuchi et al., “Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells.” Hum. Gene Ther., 10:1375-1387, 1999.
Korthauer et al., “Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency hyper-IgM” [see comments], Nature, 361:539-541, 1993.
Laman et al., “Functions of CD40 and its ligand, gp39 (CD40L).” Crit. Rev. Immunol., 16:59-108, 1996.
Mackey et al., The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells, Journal of Leukocyte Biology, 63:418-428, 1998.
Morris et al., “Incorporation of an isoleucine zipper motif enhances the biological activity of soluble CD40L (CD154).” The Journal of Biological Chemistry, 274:418-423, 1999.
Nakajima et al., “Antitumor effect of CD40 ligand: elicitation of local and systemic antitumor responses by IL-12 and B7.” J. Immunol., 161:1901-1907, 1998.
Pietravalle et al., “Cleavage of membrane-bound CD40 ligand is not required for inducing B cell proliferation and differentiation.” Eur. J. Immunol., 26:725-7, 1996.
Ranheim et al., Activated T cells induced expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J. Exp. Med., 177:925-935, 1993.
Ranheim et al., “Tumor necrosis factor-alpha facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: complex regulation by IL-4, IL-10, and CD40L.” Cell Immunol. 161:226-235, 1995.
Roy et al., “The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ cells.” J. Immunol., 151:2497-2510, 1993.
Wierda et al. “CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia.” Blood, 96:2917-2924, 2000.

Affiliated with

Also associated with

Rating

Nucleic acids encoding chimeric CD154 polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nucleic acids encoding chimeric CD154 polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acids encoding chimeric CD154 polypeptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4055332